Very Positive Media Coverage Extremely Likely to Impact Amedisys (AMED) Stock Price
Press coverage about Amedisys (NASDAQ:AMED) has been trending very positive recently, AlphaOne Sentiment Analysis reports. The research group, a service of Accern, ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a coverage optimism score of 0.56 on AlphaOne’s scale. AlphaOne also gave headlines about the health services provider an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted AlphaOne Sentiment’s rankings:
- Amedisys Inc (AMED) Scheduled to Post Earnings on Tuesday (americanbankingnews.com)
- Jefferies Group LLC Analysts Give Amedisys Inc (AMED) a $57.00 Price Target (americanbankingnews.com)
- Global Home Healthcare Market to Gain Impetus from Rising Base of Geriatric Population (reports.pr-inside.com)
- Dream Foundation and Amedisys Foundation Fulfill Hospice Patient’s Final Dream (mysocialgoodnews.com)
- Dream Foundation and Amedisys Foundation Fulfill Hospice Patient’s Final Dream (prlog.org)
A number of equities analysts have recently issued reports on AMED shares. Jefferies Group LLC set a $57.00 target price on shares of Amedisys and gave the stock a “buy” rating in a research report on Friday. Zacks Investment Research lowered shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, April 18th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $59.00 target price (up from $50.00) on shares of Amedisys in a research report on Friday, March 3rd. Mizuho upped their target price on shares of Amedisys from $33.00 to $50.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 1st. Finally, Benchmark Co. started coverage on shares of Amedisys in a research report on Friday, January 27th. They set a “hold” rating and a $50.00 target price on the stock. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $54.75.
Amedisys (NASDAQ:AMED) opened at 54.20 on Friday. Amedisys has a one year low of $34.58 and a one year high of $55.16. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 49.27 and a beta of 1.43. The company has a 50-day moving average of $51.50 and a 200 day moving average of $46.02.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, February 28th. The health services provider reported $0.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.05. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The company had revenue of $366.30 million for the quarter, compared to the consensus estimate of $368.14 million. During the same quarter in the previous year, the company earned $0.40 EPS. Amedisys’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, analysts anticipate that Amedisys will post $2.01 EPS for the current year.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.